Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferons and malignant melanoma].

B Dreno1

  • 1Service de dermatologie, Hôtel Dieu, place Alexis-Ricordeau, 44093 Nantes, France. bdreno@wanadoo.fr

La Revue De Medecine Interne
|December 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and impact of solar lentigines: An international survey.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Evolution of the sentinel lymph node procedure following the approval of adjuvant anti-PD-1 therapy for stage IIB and IIC melanoma: A multicenter study from RICMEL database.

Annales de dermatologie et de venereologie·2026
Same author

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients.

Annales de dermatologie et de venereologie·2025
Same author

Attitudes and behaviors regarding sun exposure in Japan compared to Europe and North America.

The Journal of dermatology·2024
Same author

Thirty years of promoting sun safety in France: The messages are heard but not followed!

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Do regrets of parents about sun overexposure impact preventive measures applied on their children?

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Alpha interferon (IFN-α) is a key treatment for early-stage malignant melanoma. Ongoing research explores its use in advanced melanoma and its impact on patient survival and quality of life.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Context:

  • Alpha interferon (IFN-α) is established for adjuvant therapy in early-stage malignant melanoma (primary tumor and lymph node invasion).
  • IFN-α is indicated as monotherapy for metastatic melanoma, with ongoing research into its combination with chemotherapy.
  • Beta and gamma interferons also have no contraindications for malignant melanoma treatment.

Purpose:

  • To review the current applications and future potential of interferons in malignant melanoma treatment.
  • To evaluate the efficacy of IFN-α in improving relapse-free survival and quality of life.
  • To explore novel therapeutic strategies involving interferons for melanoma.

Summary:

  • Interferon alpha (IFN-α) is utilized in early-stage malignant melanoma adjuvant therapy.

Related Experiment Videos

  • For metastatic melanoma, IFN-α is safe as a standalone treatment, with ongoing studies on combination therapies.
  • While IFN-α shows benefits in relapse-free survival, further research is needed to confirm its adjuvant role.

    • Impact:

    • Interferon therapy demonstrates a positive impact on relapse-free survival in malignant melanoma patients.
    • The quality of life for patients undergoing interferon treatment is an important consideration.
    • Pegylated interferon formulations may offer improved patient compliance through reduced injection frequency.